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Tenascin-C is a large, multimodular, extracellular matrix glycoprotein that exhibits a very restricted pattern of expression but an enormously diverse range of functions. Here, we discuss the importance of deciphering the expression pattern of, and effects mediated by, different forms of this molecule in order to fully understand tenascin-C biology. We focus on both post transcriptional and post translational events such as splicing, glycosylation, assembly into a 3D matrix and proteolytic cleavage, highlighting how these modifications are key to defining tenascin-C function.
The Multifunctional Nature of Tenascin-C Tenascin-C was independently and concurrently characterized in the 1980s by several research groups with interests in the fields of cancer, matrix biology and embryonic/neural development. Tenascin-C is highly expressed in the developing embryo in a strictly regulated spatio-temporal pattern, but most healthy adult tissues exhibit negligible tenascin-C levels. Here, expression is constrained to sites where high cell turnover, plasticity and tissue-remodeling are obligatory; such as stem cell niches and the central nervous system (CNS), in addition to regions which undergo significant tensile stress; such as tendons, ligaments and smooth muscle fibers . However, transient expression of tenascin-C is observed at sites of active tissue remodeling in the adult, such as during the healing of wounds, and persistent tenascin-C expression is detected in pathological states such as cancer or rheumatoid arthritis (RA) (reviewed in [1] [2] [3] ) Tenascin-C consists of 4 distinct domains, which can interact with pathogenic components, matrix constituents, soluble factors and cell surface proteins; conferring upon tenascin-C the ability to bind to more than 25 different molecules identified thus far. 3 For example, the tenascin assembly (TA) domain forms inter-molecular hydrophobic interactions and disulphide bridges, the epidermal growth factor-like (EGF-L) repeats act as a low affinity ligand for the EGFreceptor (EGF-R), inducing mitogen-activated protein kinase (MAPK), and phospholipase-C (PLC) -g signaling, the fibronectin (FN) type III-like repeats (FNII) interact with proteins as diverse as integrins, aggrecan, and perlecan, as well as binding to growth factors including members of the plateletderived growth factor (PDGF), fibroblast growth factor (FGF) and transforming growth factor-b (TGFb) families (Table 1) , and the fibrinogen-like globe (FBG) binds to integrins, receptor-type tyrosine-protein phosphatase zeta (PTPRz1) and activates Toll-like receptor-4 (TLR4). This enables tenascin-C to drive a range of processes from oligomerization to induction of mitogenic responses, cell migration, cell attachment, cell spreading, focal adhesion, cell survival, matrix assembly, neurite outgrowth and potentiation and protease and pro-inflammatory cytokine synthesis (reviewed in 3 ). This collection of functions is reflected in the wide ranging consequences of genetic deletion of tenascin-C in mice. Reported abnormalities include reduced FN during dermal wound healing, 4 hyperactivity, 5 reduced kidney regeneration, 6 reduced haematopoiesis, 7 increased tumor monocyte population, 8 abnormal tumor organization and angiogenesis, 9, 10 and aberrant immune responses, [11] [12] [13] among many others (reviewed in 14, 15 ) . Genetic variation at the human tenascin-C gene locus is associated with 6-fold increase in risk of Achilles tendon injury, 16 non-syndromic hearing loss, 17 and increased risk of developing adult asthma. 18 Together these data point toward very diverse biological and pathological roles for tenascin-C. Here, we discuss some of the mechanisms that exist in order to dictate how this extracellular matrix (ECM) glycoprotein can exert so many different effects.
Transcriptional Regulation of Tenascin-C
One of the foremost means of regulating tenascin-C function is via control of its expression at the transcriptional level; and the cloning, and subsequent characterization, of the tenascin-C gene has begun to shed some light on the molecular mechanisms that underpin this tightly regulated control.
Cloning the TNC gene
The tenascin-C gene (TNC) is a large intron rich gene, which in humans spans 97.68 kb of DNA on the antisense strand of chromosome 9, at locus 9q32-34/9q33.1 19, 20 and of which only »7.9% is protein coding (reviewed in 21 ). The first partial gene sequence derived for chicken tenascin-C identified several transcripts of various lengths prompting the speculation that the transcript is alternatively spliced. 22 The first human tenascin-C exon sequence was published using cDNA clones isolated from U-373MG glioblastoma cells, identifying a clone with 8 consecutive FNIII like repeats, and another clone containing the same repeats but with a 1.9 kb insert between FNIII 5 and 6; providing clear genetic evidence of alternative splicing within the tenascin-C transcript. 23 Transcriptional regulators of tenascin-C expression Expression of tenascin-C is regulated in a stimulus specific manner in humans, mice, rats and chickens; the promoter elements of which are well conserved up to around 250 bp upstream of the transcription start site (TSS), including a TATA box located 21 nucleotides downstream of the TSS. 24 Regulation of the tenascin-C promoter is influenced by many transcription factors ( Table 2 )(reviewed in 21 ). These data illustrate how tenascin-C transcription may be induced or repressed in response to different subsets of stimuli including pathogen-associated molecular patterns (PAMPs), cytokines, reactive oxygen species, growth factors and mechanical stress. More about the transcriptional regulation of all tenascin family genes is described in detail by Chiovaro et al in this issue. However, it is likely that not all of the transcription factors regulating tenascin-C expression are known; and our understanding of the details of this large TNC locus is only in its infancy. Moreover, in addition to simply turning TNC on and off, some stimuli specifically induce particular forms of tenascin-C, and this is discussed in more detail below.
Post Transcriptional Regulation of Tenascin-C
Alternative splicing allows a single gene to encode multiple proteins by the inclusion or exclusion of selected exons into the mature mRNA, dramatically increasing the size and diversity of the proteome. Up to 95% of the »21,000 protein coding genes in humans are alternatively spliced, 25 and 85% of these have a minor splice isoform with an expression frequency exceeding 15%. As a result this moderate number of genes is able to produce >290,000 non-redundant peptide combinations. 26 Following on from the first observations by Jones et al. 22 and Gulcher et al. 23 that tenascin-C is subject to alternative splicing, many studies have expanded on this theme revealing that post transcriptional modification of tenascin-C has a profound effect on tenascin biology.
Tenascin-c exon structure
The first TNC human exon sequences published showed the gene to comprise 28 exons (accession number NM_002610). However, 2 further alternatively spliced FNIII domains (additional domains 1 and 2: FNIII AD1 27 and AD2 28 (accession numbers U88892.1 and EU295718.1 respectively) were later discovered. FNIII AD1 was identified within human U251 glioma cDNA clones as a single exon between FNIII repeats B and C. This study also showed that while AD1 was present in human glioblastoma, neuroblastoma and osteosarcoma tumor cells, it was absent in healthy human lung fibroblasts and umbilical vein endothelial cells (HUVECs) providing the first indication that tenascin-C splicing may play a role in tumorigenesis. 27 Human FNIII AD2 was discovered between FNIII B and AD1 in oral mucosa carcinoma samples and was named so on account of being in the same respective location as the avian FNIII AD2; situated between FNII B and AD1, in addition to it sharing 70% amino acid and 55% nucleotide sequence homology with the avian FNIII AD2. 28, 29 Thus human TNC contains 30 exons (Fig. 1) .
Tenascin-C in other vertebrate species including chickens, rats, mice and pigs, exhibits similar domain organizations to the human protein (Fig. 2) . Each contains a TA domain, a series of EGF-L and FNIII like domains and an FBG domain. However, a number of differences exist between orthologs. For example, all vertebrate tenascin-C contains 13.5 EGF-L repeats, with the exception of mammals which possess 14.5 EGF-L repeats. 30 Furthermore, tenascin-C from humans, rats, mice and chickens each contain 8 constitutive FNIII repeats, with an additional cassette of FNIII which may be alternatively spliced between FNIII domains 5 and 6. However, the number of alternatively spliced FNIII repeats varies by species; with chickens and mice, rats, and humans having 6, 7 and 9 respectively. 28, 31, 32 Theoretically there are 511 possible human tenascin-C splice isoforms; this figure was calculated via the equation 9! 9 ¡ r ð Þ! r ð Þ! as follows,
where 9 represents the total number of alternatively spliced FNIII, "r" represents the total number of alternatively spliced FNIII included in a single variant, and "!" denotes a factorial e.g. 4! D 4 £ 3 £ 2 £ 1. Despite this large theoretical variation, the actual number of recorded splices does not exceed 100. This may partly be explained by the finding that some alternatively spliced FNIII domains are preferentially expressed together. Human FNIII AD2 is observed to be included in the transcript only when linked to AD1, FNIII C only when alongside D and interestingly FNIII A4 and C have never been observed to be linked together in mice or humans. 28, 31, 33 This partnering of multiple alternatively spliced FNIII repeats significantly reduces the possible number of tenascin-C splice variants which are observed.
Alternatively spliced isoforms of tenascin-C have been shown to play integral roles in many different processes. Here we focus Table 1 . Interactions of tenascin-C with growth factors and growth factor receptors. For studies on EGF-L repeats, [198] [199] [200] 201 and FBG. 202 Vascular endothelial growth factor (VEGF), phosphatidylinositoL-glycan biosynthesis class F protein (PIGF), bone morphogenetic protein (BMP), neurotrophin (NT), brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), insulin-like growth factor (IGF), insulin-like growth factor -binding protein (IGF-BP), connective tissue growth factor (CTGF), heparin-binding EGF-like growth factor (HB-EGF), hepatocyte growth factor (HGF), chicken acidic leucine-rich EGFlike domain containing brain protein (CALEB)
Tenascin-C Domain
Growth Factor/ Receptor Family Growth Factor/ Receptor Interaction Binding Affinity (C) No Binding Affiniy (¡) Tenascin-C splicing -development Tenascin-C is abundantly expressed during embryogenesis in neuroectodermal tissues, and subsequently in several non-neural sites where high cell-turnover, tissue remodeling and epithelialmesenchymal interactions occur (reviewed in 24 ). Typically, the overall expression of tenascin-C decreases with increasing age, generally peaking during embryonic development and shortly after birth before decreasing into adulthood when expression is restricted to a few sites at relatively low levels. 34, 35 Prior to the development of tools permitting the detection of specific alternatively spliced FNIII repeats, many studies reported the presence of high and low molecular mass (Mr) isoforms of tenascin-C, differentiated by their apparent Mr upon PAGE (PAGE) under reducing conditions, at various stages of embryogenesis in chickens, mice and rats. Further analysis utilizing in situ hybridization (ISH) and immunostaining/protein gel blotting (WB) with cDNA probes and monoclonal antibodies (mAbs) respectively, could distinguish between 'long' and 'short' tenascin-C forms; revealed that differently size splice variants are expressed in cell and tissue specific patterns that change over the course of development. These studies are described below and summarized in Table 3 .
Large versus small A good example of this derives from an elegant series of studies in the developing chick which revealed 4 main isoforms; Tn260, Tn230, Tn200 and Tn190, which have apparent Mr of 260, 230, 200 and 190 kDa respectively. 36, 37 Tn260 was rarely expressed in contrast to Tn230, Tn200 and Tn190, which were widely expressed during embryonic and early postnatal development. 38, 39 High Mr variants (Tn230/200) were associated with regions of active tissue remodeling, cell migration and cell division; evidenced by their presence in epithelial substratum for migrating neurons, embryonic skin fibroblasts, whole brain, cerebellum, chord glia, Bergmann glia, endoderm-derived epithelium at developing lung bronchioles, growing wing bud tips, base of feather buds, major blood vessel endothelium, kidney, lung, osteoblasts and regions of osteogenesis; where the expression of tenascin-C is only required transiently. 22, 34, [40] [41] [42] [43] [44] [45] [46] [47] [48] [49] In these regions, large Mr tenascin-C is expressed by migrating glia and Bergmann glia in the developing chick spinal chord and cerebellum respectively; expression in the latter of which facilitates granule cell migration. 46 In contrast, lower Mr isoforms (Tn190/200) are observed to be expressed more stably in dense connective tissue in areas such as gizzard tendons, intramuscular connective tissue, aortic mesenchyme, articular cartilage, inner layer of perichondrium and zones of active chondrocyte proliferation, where cell condensation and differentiation are more prevalent. 22, 39, 41, [44] [45] [46] [47] [50] [51] [52] Similar patterns of tenascin-C expression are observed in mice and rats, although significantly less is known about the presence of alternatively spliced tenascin-C during human fetal development. WB and real-time PCR (RT-PCR) techniques revealed that smaller Mr tenascin-C variants are the predominant isoforms expressed in E14 mouse gut mesenchyme, 53 and in the developing thymus and skin from E17 to P6 respectively. 35 Furthermore, smaller isoforms are observed to be persistently expressed into adulthood in thymus, colon, cerebellum, lymph nodes and splenic tissues. 34, 35 In contrast, the larger Mr isoforms are the predominant variants expressed in embryonic mouse kidney and in developing rat lung. 40, 54, 55 Small isoforms are also implicated in regulating development of rat lungs, where the expression of a small variant is shown to be preferentially induced by TGFb in explant cultures, 55 and low Mr isoforms have the effects of inhibiting lung branching morphology and aveolarization. 54 The splicing pattern within developing tissues was also observed to vary over time, as well as by location within the organism. For example, there is a shift in the relative abundance of splices away from large isoforms, in favor of smaller ones with increasing age in developing mouse kidney, cerebellum, skeletal muscle, stomach, bladder, duodenum, ileum, jejunum and colon. 34, 40, 56, 57 In embryonic chicken brain and gizzard, the relative proportion of smaller variants also increases with developmental age, 22, 43 as is also true in embryonic mouse intestine, gut mesenchyme, and chick cerebellum. 40, 44, 53 The smallest tenascin-C isoform, with no alternatively spliced FNIII included, is known to bind strongly to FN and the glycosylphosphatidylinositol (GPI)-anchored neural cell adhesion molecule contactin/F11 [58] [59] [60] and to promote cell attachment and the formation of focal adhesions. This is in contrast to larger tenascin-C isoforms, which prevent focal adhesion formation and drive cell migration. 61 These data imply that predominance of the larger isoform at sites of active tissue remodeling aid cell migration and dynamic tissue organization, while the smaller, pro-adhesive isoforms mediate stability of newly formed tissues toward the end of development and into adulthood. Indeed, in the prenatal chick brain, larger isoforms are abundantly expressed from E6 although the relative occurrence of smaller isoforms increases from E6 to E15; 43 and at postnatal day 3 only a single 7.2 Kda message encoding a 220 kDa peptide is detected. 44 Increased cell migration in the developing CNS was found to correlate with accumulation of long tenascin-C, but not short tenascin-C isoforms; 50, 57, 62, 63 indicating that long tenascin-C splices facilitate neurite motility in development. 64 These studies provided a wealth of information about tenascin-C splicing during development, but it is worth mentioning that 2 isoforms containing a different repertoire of alternatively spliced FNIII repeats can still exhibit the same molecular mass, as each alternatively spliced FNIII repeat is approximately the same size (89-92 amino acids), with a mass of »10 kDa each. Moreover, analysis of tenascin-C forms based purely on Mr does not allow distinction between . Schematic representation of human, rat, mouse and chicken tenascin-C. While each species contains 8 constitutively expressed FNIII repeats, the number and content of alternatively spliced FNIII repeats varies. Human tenascin-C contains 9 alternatively spliced FNIII repeats, rat 7, and mouse and chicken 6 each. Alternatively spliced repeats are typically more homologous than constitutive repeats. For example, constitutive mouse FNIII repeats share on average 44% nucleotide sequence identity to each other, in contrast to the alternatively spliced FNIII which share 52% identity. Of the mouse alternatively spliced FNIII, A2 and D share the lowest nucleotide identity at 41%, while A1 and A4 share 80%. Analysis of human tenascin-C also noted 80% amino acid sequence homology between the first 4 alternatively spliced modules (A1, A2, A3 and A4), in contrast to the other alternatively spliced FNIII repeats raising the possibility that these domains are the result of gene duplication of an ancestral FNIII module. The absence of any comparable homology between avian alternatively spliced FNIII repeats, allows for speculation that any such duplication occurred after the divergence of avian and mammalian lineages. tenascin-C that has been alternatively spliced and tenascin-C that has been proteolytically clipped. As it became apparent that each alternatively spliced FNIII repeat had unique functions, analysis of the precise FNIII repeats that make up each isoform became increasingly important.
Analysis of specific FNIII repeats
The pattern of expression of specific FNIII domains in developing tissues and the functional consequences of the expression of these different isoforms are described below and summarized in Tables 4 and 5 respectively. In both the text and tables individual splice variants separated by (,) are included in the same transcript, while those separated by (/) are not.
Developing mouse
Tenascin-C is abundantly expressed in the mouse olfactory bulb, ventricular zone (VZ) and sub ventricular zone (SVZ) of the CNS during development and postnatally [65] [66] [67] where it has been shown to orchestrate the development of niches permitting the development of neural stem cells (NSC) altering their response to FGF-2 and BMP-4. 68 Embryonic and postnatal day 6 mouse cerebellum express 4 and 27 different major mRNA isoforms respectively, of which the largest decrease in expression faster than the shorter variants during neural development. 31, 56 Similarly, NSCs express 20 isoforms which are differentially regulated by Pax6 and Sam68 transcription factors. 69, 70 In NSCs, expression of the largest isoform comprising FNIII-A1,A2,A4,B, C,D was demonstrated to contain N-and O-linked natural killer-1 (HNK-1) carbohydrate epitopes; 71 first described on tenascin-C by Kruse et al. 72 HNK-1 epitopes; otherwise known as CD57 are named after the HNK-1 mAb, and are found on the surface of a subset of T-lymphocytes and natural killer (NK) cells, but also on a number of cell adhesion molecules distributed throughout the nervous system including myelin-associated glycoprotein, 73 neural cell adhesion molecule, 74 and L1 cell adhesion molecule. 75 HNK-1 has functions in cell-cell and cellsubstrate interactions, and promotes NSC proliferation via modulating the expression of the EGF-R. 71 Further functional studies demonstrated how tenascin-C splice variants are capable of modulating the response of neurons during CNS development. In E18 rat and P6 mouse neurons, FNIII-A1,A2,A4,B,D coated plates, supported initial attachment. 76 FNIII-B,D/ D,6 and 6 containing isoforms facilitate neurite outgrowth in P6 granule cell neurons and E18 rat hippocampal, P0 mouse dorsal root ganglia explants respectively, and even increase the proportion of neurite bearing cells in culture. 76, 77 Mercado et al. 78 demonstrated that the FNIII-D repeat is strongly inductive of neurite outgrowth on account of 2 short sequences within the VFDNFVLK amino acid sequence, which permit interactions with a7 and b1 subunit containing integrins. The FNIII-A1,A2,A4 region in contrast is anti-adhesive and was demonstrated to promote neuronal migration and repulsion in rat E18 and P0 mouse root dorsal ganglia neurons, 76, 77 and E16 rat cortical and thalamic axonal outgrowth. 80 Nearby dental mesenchyme papilla expressed FNIII-D following induction by FGF-4 and TGFb, the latter of which also induced the expression of a long mRNA variant containing 5 alternatively spliced FNIII repeats. Interestingly, the response of dental mesenchyme papilla to growth factor induction always occurred in E12 but not always in E11, suggesting that the dental mesenchyme becomes responsive to the induction of tenascin-C at some point during E11.
80
In the mammary gland, full length tenascin-C isoforms are highly prevalent during involution, and recombinant proteins containing FNIIIA1-D inhibit milk protein synthesis, suggestive of a role for tenascin-C in facilitating the cessation of lactation in mammals. 81 
Developing chicken
In Situ hybridization (ISH) experiments using cDNA probes complementary to FNIII AD2 or C revealed a strict spatial pattern of tenascin-C splicing in the developing chick. These probes did not hybridize to chondrogenic or osteogenic regions; while AD2 cDNA probes did hybridize at regions of epithelial-mesenchymal interactions including lung bronchioles and the base of feather buds. 28, 48 In contrast probes for AD1 and A,B hybridize strongly in almost all regions where tenascin-C is detected in the E10 chick embryo, such as feather buds, lung bronchioles, tendons, ligamentum flavum, cartilage and bone; with exceptions including spinal cord glia and sternal perichondrium. 28, 48 In developing bone, up to 85% of the tenascin-C transcripts detected via quantitative immunohistochemistry (IHC) included the AD1 repeat. 49 FNII-C localizes in a pattern which exclusively overlaps the expression pattern for FNIII-A,B, with the exception that FNIII-C cDNA probes never hybridize in the spinal cord, or aorta endothelium, indicating a more tightly regulated pattern of expression in this location. 29 Functionally, tenascin-C was shown to promote adhesion and outgrowth of E3 spinal cord, E8 sensory, E8-11 sympathetic and E6 retinal ganglion cell neurons in chickens. [82] [83] [84] In CNS neuron neurons this effect was mediated by FNIII-A, but in peripheral nervous system (PNS) neurons was mediated by FNIII-A and 3. Cell adhesion to FNIII-A and 3 was inhibited by anti-b1-integrin antibodies, and arginylglycylaspartic (RGD) peptides respectively, illustrating that the adhesive effects of FNIII-A on neurons is b1-integrin dependent. 85 In chicken embryos, the expression of isoforms containing FNIII-AD2/AD1/ and C are dramatically up-regulated at sites of active tissue remodeling and FN expression within the developing feather-bud and sternum. In vitro these variants have been shown to decrease cell attachment and organization of actin microfilament bundles in myoblasts cultured on FN. 86 However, cells bound to a FNIII-AD2/AD1/C containing substrata developed stronger adhesions than those bound on tenascin-C containing no alternatively spliced FNIII, but did not form focal adhesions as is the case on FN. Instead they formed F-actin microfilament bundles at non-uniform adhesion points, giving the cells an irregular shape much like when adherent cells are cultured on thrombospondin-1. 86, 87 The introduction of alternatively spliced FNIII modules may conversely disrupt adhesions between tenascin-C and other ECM molecules, as was demonstrated by FNIII A/B/C splices binding less strongly to FN and the GPI-anchored immunoglobin-superfamily neural cell adhesion molecule contactin/F11. 58 This is because in contactin/F11, the first 3-Ig domains preferentially bind to the uninterrupted FNIII-5,6 region; 59 as a result, contactin/F11-tenascin-C binding is attenuated by the inclusion of alternatively spliced FNIII in the tenascin-C molecule which interrupt this binding region. 58 Larger chick tenascin-C isoforms possess annexin II binding ability, and hence promote proliferation, cell migration and induce loss of focal adhesions hence encouraging cells cultured on high Mr tenascin-C to become motile. 88, 89 In addition, contactin/F11 binding to FNIII-5,6 was shown to be inhibited by heparin sulfate and dermatan sulfate. 60 All in all, the inclusion of adhesion modulating FNIII repeats such as AD2/AD1/C in the developing chick embryo create an environment conducive to tissue remodeling by permitting changes in motility, adhesion and cell shape.
Developing rat AD1 containing variants are found in the highly plastic SVZ and dentate gyrus of the developing rat brain, with an observable shift in expression from shorter to longer isoforms as development progresses from embryonic day 1 to postnatal day 5. 32 An early mAb perturbation study revealed that FNIII-4,5/A1,A2, A4/ D but not the EGF-L was required for axonal outgrowth from E16 cortical and thalamic explants. 79 In vitro, FNIII-C facilitates the orientation of rat cerebellar granular neurons, but has no effect on outgrowth. 90 The variable rat FNIII B-D promotes contactin/F3 dependent neurite outgrowth when FNIII-C is excluded from the transcript; as its inclusion disrupts the contactin/F3 binding site formed between the adjacent FNIII-B and D. 91 FNIII-B,D containing tenascin-C is widely reported to promote neuron outgrowth in embryonic rat hippocampal neurons, mesencephalic neurons, cortical astrocytes and retinal neurons. 76, [91] [92] [93] [94] This repeat has a conserved function in P6 mouse cerebellar neurons, where it does not alter the rate of cell proliferation, but does increase the proportion of neurite bearing cells in culture. 77 Similarly to mouse neurites, FNIII-D also promotes rat neurite outgrowth in a manner dependent on Ca 2C , PLC, protein kinase-C and contactin. 95 The outgrowth of E18 rat Interestingly the abundance of FNIII-B,C in regions of high cell motility and turnover led some investigators to assess any potential functions of the repeat in developing organs outside of the CNS. However, despite a high abundance of tenascin-C in the E14 rat kidney mesenchyme, antibody perturbation of FNIII-B,C and A1,A2,A4 failed to exhibit any negative effect on the development of the kidney, suggesting that in an in vivo model at least, the presence of alternatively spliced FNIII in these tissues have no developmental function. 95 The model did not take into account the potential roles of variable FNIII repeats on in vivo specific processes in development, such as vascularization which would make good considerations for the future.
Developing human
A wealth of tenascin-C splice variants was found within human fetal membranes which encapsulate the developing fetus and amniotic fluid. Bell et al. 96 identified 8 different tenascin-C splice variants containing between 0 and 7 spliced FNIII repeats, which were speculated to promote spontaneous membrane rupture during labor by contributing to tissue remodeling processes in a manner analogous to a wound response. The predominant isoforms detected by RT-PCR contained FNIII-D/ and A1-A4, either with or without FNIII-A3. 96 The selective inclusion/exclusion of tenascin-C isoforms containing repeat FNIII A3, may provide functional significance with regard to mediating the susceptibility of tenascin-C to proteolytic degradation by matrix metalloproteinase (MMP) -2 and 3; both of which can cleave tenascin-C at a site located within the FNIII A3. MMP-7 also exhibits protease activity, and can digest tenascin-C between FNIII repeats A3-D; 96, 97 perhaps facilitating fetal membrane rupture prior to birth. In this way, 'long' tenascin-C isoforms would be susceptible to MMP-2, 3 and 7 mediated fragmentations, whereas 'small' tenascin-C isoforms lacking A3 would be resistant. This process may generate a novel regulatory pathway where FNIII A3 containing isoform dependent processes can be regulated by MMP-2 and MMP-3.
96
Tenascin-C splicing -cancer Tenascin-C is abundantly expressed in the stroma of many solid tumors (reviewed in 1, 98, 3 ). In addition to elevated tenascin-C in tumors, the splicing pattern often differs compared to healthy tissues. Studies examining 'long' and 'short' tenascin-C isoforms are summarized in Table 6 , while Table 7 details specific alternatively spliced FNIII detected in tumors and Table 8 the functional consequences of particular FNIII repeats on tumor cell biology.
Tissue levels of large tenascin-C variants What little tenascin-C is present in healthy or benign tissues generally consists of the small variant containing no alternatively spliced FNIII repeats (Mr 180-190 kDa) . In contrast, a range of larger isoforms with Mr 210, 220, 230, 250, 260, 280, 320 and 330 kDa, which would be predicted to contain one or more alternatively spliced FNIII repeats, have been described to be deposited in the ECM of a variety of human tumors including breast, colon, bladder, ovaries, prostate, pancreas, kidney, liver, uterus, brain, mouth, lung, skin, cartilage, connective tissues and peripheral nervous system ( Table 6) .
For example, total tenascin-C expression was observed to dramatically increase in invasive and intraductal breast carcinomas relative to normal breast tissues, with 2 major isoforms of 180 kDa and 250 kDa detectable via WB. 99 Subsequent analysis revealed that 85% of tenascin-C in normal breast tissue is a small 180 kDa isoform, but in malignancy the larger 330 kDa variant becomes predominant, with the small isoform always accounting for less than 40% of the total tenascin-C. 100 Similarly, elevated expression of large tenascin-C isoforms relative to smaller ones in lung cancer, was reported by Oyama et al. 101 who found elevated mRNA isoforms encoding a large tenascin-C variant with 7 alternatively spliced FNIII repeats in 6 of 10 adenocarcinomas, and 3 of 3 squamous cell carcinomas (SCCs) tested.
However there are exceptions to this rule; the expression of tenascin-C in cancer is highly polymorphic, depending on the type of cell involved, and the stage of disease. This is evidenced by examples of cancers where the smallest tenascin-C isoform is predominantly expressed, such as in some renal, colon and breast carcinomas. 99, 102, 103 Association of large isoforms with disease progression A number of studies have suggested that large tenascin-C isoforms may correlate with prognosis, invasion and cancer progression in the bladder, brain, colon, lung, breast, B-cell nonHodgkin's lymphoma, and adipocytic tumors. Furthermore, the presence of these large isoforms in some cases can also indicate disease recurrence and chemotherapy resistance ( Table 6 ).
In the case of non-small cell lung carcinoma (NSCLC), an 18-fold increase in the expression of large tenascin-C variants was predictive of disease recurrence. 104 Similarly, large 8 kb mRNA variants correlated with high stromal cellularity in breast cancer, and 330 kDa protein variants with extra domain-B containing FN (EDB-FN) positive colon cancer; linking large tenascin-C isoform expression with a tumor permissive stroma and the presence of invasive and angiogenic tumor marker protein EDB-FN, the expression of which is otherwise absent in healthy tissues. 100, 105 Likewise, in normal and benign breast cancer, the 190 kDa isoform was predominantly expressed, with a shift to expression of large 330 kDa variant in invasive disease. Furthermore in 3 of 16 cases of invasive disease, a number of intermediate splice variants were identified which suggested that while stromal cells are capable of synthesizing tenascin-C of 2 major isoforms, 190 and 330 kDa, epithelial cells can express tenascin-C isoforms of intermediate mass. 100 Again though, while elevated tenascin-C expression in tumors is often associated with poor prognosis and patient outcome, there are many examples of tumors where there is no such correlation. There is no correlation between tenascin-C expression and prognosis or disease stage in stomach adenocarcinoma; 110 There are also cases where tenascin-C expression is absent in poor prognosis tumors, such as in cases of cervical carcinoma. 111 Other studies found no associations between tenascin-C expression pattern and a number of clinical features such as nodal metastasis, tumor necrosis or blood vessel invasion in 32 invasive breast carcinomas. 112 Interestingly, one study found that in colorectal carcinoma (CRC) low expression of tenascin-C is associated with lymph node metastasis, perhaps indicating that in some cancers tenascin-C is capable of enforcing some anti-metastasis mechanisms. 113 Specific FNIII repeats and their association with tumors Technological advances in the field now permit the identification of specific spliced tenascin-C variants in cancer, and many studies have used these tools to identify subsets of tenascin-C isoforms, or single alternatively spliced FNIII repeats in tumors. While a systematic analysis of every splice variant in specific tumors is for the most part still lacking, these studies illustrate the distribution of specific FNIII repeats in malignancy, and shown that in some cases distinct FNIII repeats are associated with increased tumor grade, invasion, migration and metastases ( Table 6) .
For example, many IHC studies have utilized mAbs specific to regions FNIII-A1/A4, such as BC-2; showing that FNIII A1/A4 containing variants are not detected in normal cells, but are found at the tumor invasion front with apparent associations with migrating tumor cells. In oral SCC FNIII-A1, A4 containing variants are localized to the tumor stroma at the interface near invading cells, with greater expression correlating with higher disease stage. 114 Similarly, FNIII-A1,A4 and A3,A4,B are absent in normal prostate, yet strongly localized to neoplastic glands and the tumor invasion front in prostatic adenocarcinoma by IHC and ISH respectively. 115 In addition, FNIII-C containing tenascin-C isoforms were identified in brain cancer tissues via IHC using the mAb TN-11, 116 and subsequently using a catalog ISH probes and RT-PCR techniques. This study found strong associations of FNIII-C with high grade astrocytoma and glioblastoma, cerebral cavernomas and lung cancers where the distribution of FNIII-C was consistently associated with tumor stroma, tumor blood vessels and proliferating cells in these tissues. [116] [117] [118] Likewise, FNIII-B containing tenascin-C isoforms co-localize to laminin-5/g2 in the basement membrane region of oral SCC, where increased expression positively correlates with malignancy grade. 119 Another study revealed by IHC and RT-PCR that invasive urothelial cell carcinoma (UCC) exhibits restricted expression of FNIII-A1/ B or D which is closely associated with tumor blood vessels, invasive tumor stroma and damaged muscle. Moreover, the same study identified an association between AD1 and a compact invasion pattern. 120 Similarly, the preferential expression of tenascin-C isoforms containing FNIII repeats B/ D/ AD1/ AD2/ B,D and B,AD1,D is well characterized in breast cancers including ductal carcinoma in situ (DCIS) and is known to occur at the tumor invasion front, and in cancers with elevated risk of metastasis. 49, [121] [122] [123] [124] These isoforms were originally thought to be tumor specific; although a more recent study identified FNIII-AD1 and AD2 expression in the myoepithelium of larger normal ducts in the breast, while also detecting their presence in 34.9% and 23.1% of invasive breast carcinomas respectively. 123 There is also a clear correlation between expression of AD1 and AD2 containing tenascin-C isoforms and invasive estrogen receptor negative breast cancer in younger women (40 y of age), however no such correlation was observed between FNIII-AD1 and AD2 prevalence with human epidermal growth factor receptor 2 expression. Since one of the primary chemotherapeutics for the treatment of breast cancer is the ER antagonist tamoxifen, the prevalence of FNIII AD1 and AD2 may be suitable as predictor for tamoxifen-resistant breast cancer, or breast cancer which is not yet tamoxifen resistant; yet may become so. In this way, surveillance of the tenascin-C isoform expression pattern could positively impact patient treatment. 123 Other IHC studies illustrated how the pattern of tenascin-C splicing changes dynamically during disease progression. For example, anti-FNIII-D mAbs stained strongly in early stage I/II CRC, but less so in later stage III/IV tumors and liver metastases. However, FNIII-A1,A2,A4 containing isoforms were much more abundant in metastases then early stage tumors demonstrating a shift in expression from FNIII-D to A1,A2,A4 during the development of CRC. 125 These observations may prove useful in cancer patient diagnosis or stratification. For example, Driemel et al. demonstrated the diagnostic potential of combining hematoxylin and eosin staining with BC-2 IHC, in atypical oral brush biopsies, which would allow for the additional detection of FNIII-A1/ A4 containing isoforms. This combination protocol increased the sensitivity and specificity of conventional HE staining from 96 to 99% and 78 to 95% respectively. 126 
Consequences of FNIII repeat expression in cancer
Tenascin-C possesses the ability to modulate cell behavior in normal, tumor and tumor-associated cells in a manner which is cell-type specific, and which may either directly or indirectly affects cancer initiation and progression. Functional studies have identified roles for large tenascin-C variants in promoting a tumor supportive tissue microenvironment, with early studies identifying roles in the down-regulation of focal adhesion activity, 127 promotion of cell migration, 50 up-regulation of ECM degrading enzymes 128 and prevention of binding to FN; 39, 61, 129 processes which would favor the development of malignancy by reducing adhesion and facilitating cell migration ( Table 8) . Human Small (220 kDa) and large (320 kDa) Chondrosarcoma Exogenous addition of 320 kDa isoform stimulates twice the levels of MMP-1 expression observed when adding 220 kDa isoform. Thirty-fold activation of MMP-1 promoter by 320 kDa isoform, compared to 220 kDa isoform. Furthermore, collagenase and invasion activity of chondrosarcoma increased 3-fold in 320 kDa variant treated cells Galoian et al.
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Large tenascin-C isoforms may promote the destruction of the local tissue environment during tumorigenesis and metastasis by inducing the expression of ECM degrading enzymes such as MMP-1 in chondrosarcoma 128 and MMP-13 in breast cancer. Although here MMP-13 expression is accompanied by increased levels of TIMP-3, and was not tenascin-C isoform specific. 130 The degradation of the ECM and the driving of an epithelialmesenchymal transition is crucial in the process of tissue invasion as observed in metastasis. In chondrosarcoma, addition of the large 320 kDa tenascin-C isoform conferred a 3-fold increase in collagenase and invasion activity via modulation of MMP-1 expression. 128 Functional studies in human cells have also served to elucidate the role of specific tenascin-C isoforms in malignancy, and these have been best characterized in breast cancer (reviewed in 124 ). AD1 containing isoforms promoted cell growth and invasion above control levels in breast cancer cells. 123 These data are supported by previous findings of FNIII-AD1 expression in breast ductal carcinoma, melanoma, retinoblastoma, basal cell carcinoma cell lines and in highly invasive Japanese quail fibrosarcoma cells (QT6 cell line).
49 QT6 predominantly express a major 230 kDa isoform containing 3 alternatively spliced FNIII, although minor isoforms containing 0, 1, 2 and 4 spliced FNIII are detected in low abundance. FNIII-AD1 is abundantly expressed in QT6 cells, and correlates with these cells exhibiting invasive capabilities as demonstrated in a Boyden chamber assay where they passed through a FN coated filter. 49 Other studies have also identified AD1 containing tenascin-C isoforms at sites of high cell motility. 131 Together, these findings may suggest that AD1 containing tenascin-C isoforms modulate cell-FN interactions and contribute to a tissue microenvironment that facilitates changes in cell morphology, proliferation and migration in cancer. 49, 123, 131 Large tenascin-C isoforms have been directly implicated in the induction of proliferation, migration and control of cell spreading in vitro. MMP-2 mediated proteolytic cleavage of large tenascin-C variants reveals a cryptic syndecan-4 binding site within the FNIII-A2 domain. Here, a 22mer fusion peptide containing an adhesive YTITIRG sequence bound to the heparin sulfated side chains of the b1 integrin co-receptor synecan-4, hence inducing cell adhesion and spreading on FN. 132 This study found that mutation of the cytosolic region of syndecan-4 had no effect on promoting the inhibition of b1 integrin action, suggesting the extracellular portion of syndecan-4 binds FNIII-A2 and hence promotes b1 integrin clustering and activation, rather than mediating this effect via downstream targets of syndecan-4. Elevated levels of both activated MMP-2 and degraded tenascin-C were identified in NSCLC, with proteolytically degraded tenascin-C serving as a good indicator of stage-1 NSCLC recurrence. 133 It is therefore possible to speculate a role for MMP-2 in degrading tenascin-C in lung cancer, and that FNIII-A2 cryptic site interaction with syndecan-4 in lung tissues play a role in mediating early stage recurrence of the disease.
A follow up study identified that sustained activation of a5b1 by the FNIII-A2 cryptic site caused non-transformed mouse embryonic fibroblasts NIH-3T3 to become resistant to serum deprivation-induced anoiksis by activating the pro-survival Akt/ Bcl-2 pathway, and enhanced PDGF-dependent proliferation of NIH-3T3 cells via promoting the association between PDGF receptor b (PDGF-Rb) and the activated molecular complex that comprises of a5b1 and syndecan-4. 134 This extended the activation of the PDGF-Rb and its downstream Ras/MAPK pathways. Furthermore, the study suggested that tenascin-C may de-regulate cell growth processes by triggering the continual activation of a5b1 by the FNIII-A2 cryptic site; this mechanism was implied by the observation that confluent monolayers of fibroblasts continued to proliferate in an a5b1 dependent manner, and had apparently overridden their innate cell-density mediated cell cycle arrest mechanisms. 134 This demonstrates a highly significant role for MMP-2 cleaved tenascin-C in the promotion of cancer.
Chung and Erickson., 88 first showed that the large tenascin-C isoform containing the full alternatively spliced FNIII cassette is a high affinity binding partner of the cell surface located calciumdependent phospholipid-binding protein annexin II, binding of which reduces focal adhesions, enhances mitogenesis and promotes cell migration. 89, 127 Similarly, addition of full length tenascin-C to pancreatic cancer cells ameliorated the cytotoxic response to chemotherapeutic agent gemcitabine, in a manner which was dependent upon binding between FNIII A1-D and cell surface annexin II. 135 Addition of recombinant FNIII A1-D increased the intracellular phosphorylation status of protein kinase B signal cascade constituents including PI3k, Akt, IKKa and NF-kB. 135 Although in this study the effects of FNIII A1-D were not assessed in the context of promoting cell survival, proliferation or growth, such phosphoproteins are central mediators of these processes; for example, phospho-Akt is a major promoter of cell survival and effects this via phosphorylating and hence inactivating a number of pro-apoptotic target proteins including Bad, Bax, Bim and Forkhead transcription factors (FOXOs). 136 The anti-FNIII-B mAb 4C8MS attenuated in vitro migration and mitotic activity in intraductal breast cancers. 122 Functional overexpression of FNIII-D/ B,D and B,AD1,D in human breast cancer cell lines or FNIII B and B,D in fibroblasts significantly increased proliferative and invasive capabilities of breast cancer cells compared to vector controls in vitro; in addition to inducing a 2-and 4-fold increase in expression of MMP-13 and TIMP-3 respectively. 123, 130 Interestingly, during embryonic development, FNIII B and D promote neurite outgrowth in a manner dependent upon interactions with the F3/contactin and a7b1 integrin, 78, 91 permitting speculation that conserved mechanisms promoting cell migration in embryogenesis are being re-activated in tumorigenesis.
A further antibody perturbation study determined that specific splice variants of tenascin-C containing FNIII-D reduced immune surveillance in solid tumors, evidenced by the large tenascin-C variant inhibiting CD3-FN mediated lymphocyte proliferation and interferon-g (IFNg) production in tumor invading lymphocytes. 104 The presence of FNIII-D would therefore be expected to be accompanied by increased tumor recurrence rates on account of an impaired immune clearance mechanism. Interestingly, Parekh et al. 104 found that large 250 kDa isoform expression is increased 18-fold in recurrent NSCLC compared to non-recurrent NSCLC; which if presuming FNIII-D expression was increased also, would be consistent with this hypothesis.
Serum levels of tenascin-C Without taking into account individual splice isoforms, global serum levels of tenascin-C have been shown to have either diagnostic or prognostic functions in pancreatic adenocarcinoma, 137 CRC (healthy control 3.2C/¡1.7 mg/ml, CRC mean 5.0C/ ¡4.2 mg/ml, CRC without metastases 4.3C/¡3 mg/ml CRC with metastases 6.8C/¡6 mg/ml), 138 inflammatory bowel disease (healthy control 3.2C/¡1.7 mg/ml, prior to surgery for ulcerative collitis (UCC) 17.2C/¡ 4.6 mg/ml, ulcerative collitis C ongoing medical treatment, median 5.3 mg/ml, Crohn's disease C ongoing medical treatment, median 4.9 mg/ ml), 139 melanoma (healthy control 444C/¡ 171 ng/ml, stage I/ II melanoma 419C/¡103.3, stage IV melanoma 782.6C/ ¡629.5), 140 and auto-immune bullous diseases of the skin,.
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In NSCLC patients tenascin-C is cited as a predictive biomarker of angiogenesis, and levels above 96 ng/ml in patient serum inversely correlate with patient survival. 142 However in diseases like breast cancer and ovarian cancer where serum levels of tenascin-C are elevated from 137 § 26.8 pg/ml and 90.1 pg/ml to 344.1 § 42.4 pg/ml and 130.5 pg/ml respectively, there is no predictive or prognostic function in relation to patient survival; 143, 144 with another study identifying elevated serum tenascin-C levels as a dubious tumor biomarker as serum levels also increased in during infection and as a consequence of inflammation. 145 Two studies identified elevated serum levels of FNIII-C as a suitable tumor biomarker for CRC (healthy control 2364.3C/ ¡749.6 pg/ml, primary CRC 5260C/¡3243.3 pg/ml, recurrent CRC 4160C/¡2261.1 pg/ml), where it exceeded the sensitivity of conventional CRC diagnostic tests for serum markers carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) at 40.1% and 23.6% respectively, and diagnosed CRC with 56.6% sensitivity, 146 furthermore elevated serum levels of FNIII-C were associated with hepatic recurrence of CRC metastases. 147 Urine levels of FNIII-B from patients with UCC and urothelial carcinoma of the urinary bladder (UBC) have been quantified in several studies using commercially available ELISA kits (FNIII-B containing isoforms: healthy control 200 ng/ml, cystitis 650 ng/ml, pTa grade UBC »1000 ng/ml, pT3-4 grade UBC »8500 ng/ml, FNIII-C containing isoforms: healthy control »60 ng/ml, cystitis »200 ng/ml, pTa grade UBC »200 ng/ml, pT3-4 grade UBC »990 ng/ml) (FNIII-B containing isoforms: non-muscle invasive UBC »2.4 ng/ml. nonmuscle invasive relapse »2.9 ng/ml, muscle invasive relapse »8 ng/ml). 148, 149 While proteolytic fragmentation of tenascin-C was observed in the urine from invasive UCC patients, and was indicative of enhanced protease activity and tissue destructive disease, 148 FNIII-B concentration in UBC patient urine could predict existence or recurrence of a tumor, and also whether the disease was muscle invasive. 149 The first study also quantified urine levels of FNIII-C containing isoforms, although these were found not to be indicative of disease stage in UCC patients. 148 However, the number of cancers where serum levels of tenascin-C sufficiently correlate with disease progression is low and tenascin-C would appear an unsuitable universal cancer biomarker as had perhaps once been hoped. Moreover, the serum levels of tenascin-C detected in healthy controls vary vastly from one study to another, which may partly be explained by use of different ELISA kits and sample preparation, but not wholly, as many of these studies use comparable methodology. Therefore at the current time, in some specific disease types, serum or urine tenascin-C surveillance may improve diagnosis when combined with already existing techniques. Interestingly, tenascin-W exhibits an even more restricted expression pattern in normal tissues than tenascin-C and has been proposed as a superior biomarker for malignancy. 150 Therapeutic exploitation of tenascin-C splice variants The strong association between the expression of alternatively spliced FNIII repeats of tenascin-C with tumors, and in many cases very aggressive tumors, combined with their reduced expression in normal healthy tissues has raised interest in pharmacological targeting of these modules. These studies are extensively reviewed in, 3 and are therefore only summarized below. Most studies to date have focused on using antibodies to alternatively spliced FNIII domains to deliver cytotoxic or antiinflammatory factors direct to the tumor, but given the active role these domains play in driving tumor cell biology, there also exists the potential for developing antagonists of these domains for use in cancer treatment. Antibodies specific for FNIII-A1 (F16) and FNIII-C/D (81C6) have been best characterized, although others are in development. 131 I-labeled 81C6 has been trialled as a therapeutic in malignant glioma where it targets residual cancer cells following brain surgery. 151 131 I-81C6 increased median survival of glioblastoma multiforme patients, although correlations were observed between irreversible neurotoxicity and decreased survival. Nevertheless, 131 I-labeled 81C6 delivers highly targeted radio-isotope therapy and is now undergoing phase III trials with the trade name Neuradiab. 152, 153 Three other anti-tenascin-C antibody conjugates are currently under development, all of which use the FNIII A1 targeting antibody F16.
154 F16 is conjugated with interleukin (IL) -2, 131 I, and 124 I for the therapy of lung and breast cancer, Hodgkin's lymphoma and various tumors respectively.
153 F16-IL-2 is reportedly a highly efficacious and safe immunotherapeutic when administered in combination with the chemotherapeutic temozolomide to BALB/c nude mice with sub-cutaneous and intracranial human glioblastoma tumors, F16-IL-2 induced a complete remission in these animals, and promoted leukocyte infiltration of the tumors. Following complete remission, the mice remained tumor free for 160 d 155 The latest instalment in this exciting story is published in this issue in the article by Catania et al, who report data from a phase Ib/II trial administering F16-IL2 cytokine fusion proteins in combination with doxorubicin to patients with solid tumors and metastatic breast cancer.
Alternative splicing beyond development and cancer Alternative splicing of tenascin-C is not restricted to developing tissues and tumors, but is more likely a universal feature of tenascin-C expression during tissue remodeling. Indeed 22 different tenascin-C splice isoforms were identified in pseudophakic and aphakic bullous keratopathy corneas, with the predominant isoforms containing one, 2, both or neither of the FNIII A1/D modules. 156, 157 These data suggest that a detailed and systematic examination of tenascin-C splicing will reveal important information about the role of this molecule in different locations. Using well-established PCR techniques requiring the generation of primers to flank the alternatively spliced region and subsequent ISH, cloning and sequencing of the expanded PCR products, 31, 69 or exploiting the ability of deep sequencing technology to identify all mRNA species present within cells of different tissues and lineages, will help to reveal the full picture of this post transcriptional modification of tenascin-C at the mRNA level.
Regulation of tenascin-C splicing As described above, tenascin-C splicing is regulated in a very distinct spatio-temporal manner, which is clearly observed during embryogenesis and in numerous pathological conditions. The mechanisms by which this complex process is controlled in such a highly orchestrated time and location dependent manner are beginning to emerge.
The regulation of tenascin-C expression is mediated by growth factors and cytokines in a situation-specific response. During embryogenesis in humans and mice, tenascin-C expression is upregulated by TGFb. 47, 158 TGFb-1 provides the most significant upregulation of tenascin-C although expression is also responsive to TGFb-2, -3 and -5. 159 TGFb-1 is also observed to induce preferential expression of the small tenascin-C isoform lacking FNIII A1-D in endometrial adenocarcinoma and NIH-3T3 cell lines. 160 In vivo, tenascin-C expression closely correlates with expression of TGFb in the heart, bone marrow megakaryocytes, breast cancer, ovarian cancer and inflamed joints. 161, 162 FGF is also a potent inducer of tenascin-C expression, with the expression pattern of FGF2 in the mouse CNS corresponding with that of tenascin-C. 47 In addition to FGF up-regulating tenascin-C expression on the whole, FGF1 and FGF2 has been shown to preferentially induce the expression of large tenascin-C splice variants in the lateral ventricles of the rat brain, and the NIH-3T3 fibroblast cell line respectively. 47, 160, 163 The expression of tenascin-C is influenced by the presence of pro-inflammatory cytokines, which also can either up-regulate the expression of all tenascin-C isoforms, or induce the preferential expression of long (tenascin-C isoforms containing one or more alternatively spliced FNIII), or short isoforms (containing no alternatively spliced FNIII). This effect has been investigated in keratinocytes, where IL-4 has been shown to induce the expression of short and long mRNA transcripts equally, with a relative abundance of 1:1.5. In contrast, the potent immune-activator tumor necrosis factor-a (TNFa) preferentially induces the expression of short tenascin-C transcripts, while IFNg favors the expression of long transcripts. 164 Another important regulator of tenascin-C splicing is intracellular pH (pHi). In cell cultures of lung and dermal fibroblast cell-lines, a physiological pH »7.0 results in the expression of small tenascin-C splice isoforms lacking the alternatively spliced FNIII domains A1-D. However when cells are exposed to more basic pH »7. 30-7.50 as is the case in artificial culture experiments, fetal tissues and aggressive tumors, tenascin-C expression switches to the longer-isoform with one or more alternatively spliced FNIII repeats included in the transcript. 153, 165, 166 pH regulation of tenascin-C splicing may therefore contribute to the diverse range of tenascin-C splice variants which are found in human fetal membranes. 96 Similarly, malignantly transformed fibroblasts principally express large tenascin-C isoforms regardless of the extracellular pH in vitro (pHo); interestingly, this is because these cells maintain a basic pHi throughout a wide range of pHo. 166 Bumke et al., 167 confirmed that the large isoform is preferentially expressed at basic pHo, but that serum starvation in fibroblasts reduces expression of the large tenascin-C isoform; independent of culture media pH.
Most recently, the splicing factor protein SRSF6 has been identified as a regulator of tenascin-C alternative splicing. SRSF6 induction in transgenic mice resulted in expression of full-length tenascin-C isoforms, which were absent in normal uninduced skin. The presence of the full-length tenascin-C isoform accompanied hyperplasia of keratinocytes, although this effect and the abundance of full-length tenascin-C could be reverted following removal of SRSF6 induction.
168 SRSF6 mediated alternative splicing regulation of tenascin-C results in the excessive proliferation of keratinocytes in response to tissue injury, and therefore SRSF6 can modulate tissue homeostasis in vivo by promoting the expression of long tenascin-C isoforms in preference to shorter ones.
Post Translational Regulation of Tenascin-C
In addition to control of tenascin-C function at the transcriptional and post transcriptional level, the impact of tenascin-C on cell phenotype is profoundly affected by modifications to the protein after translation.
Tenascin-C biosynthesis
Following translation, tenascin-C assembles intracellularly into a 1.1-2.0 MDa 6-armed hexabrachion structure comprised of 6 monomers. 169 This process is largely determined by N-terminal residues which are arranged into 3 cysteine-rich heptad repeats which form a coiled-coil region (amino acids 118-145 in human tenascin-C); 38, 170 a feature common to other oligomeric matricellular proteins such as thrombospondin and cartilage oligomeric matrix protein-1. 171 Coiled-coils have a repeat pattern of hydrophobic and charged amino acids arranged as hxxhcxc (denoted a-g) called a heptad. In tenascin-C, these repeats produce short a-helices in which residues a and d form a 3,4-hydrophobic repeat, creating a stable non-polar core buried at the center of the helix. This stable arrangement projects the charged Cysteine side-chains at positions e and g out from the helix, where they can promote the oligomerization of tenascin-C subunits by forming inter-chain di-sulfide bonds. 170 Two models for tenascin-C oligomerization have been proposed. In one model this event is a rapid co-translational process where 6 monomers are simultaneously assembled into a single hexabrachion in as little as 60 minutes following translation initiation. These data are based on pulse-chase analysis which revealed an absence of any intermediate oligomers suggesting that assembly is initiated at the N-terminus and completed in a single step, before translation is completed. 171 This contrasts with models of assembly described for other large ECM proteins such as collagen, FN and vonWillebrand factor which are all assembled post-translationally from C-terminal assembly start points. In this model, 6 ribosome-associated polypeptide chains would have to multimerize simultaneously during translation. It has been suggested that the conformation of poly-ribosomes on the surface of the endoplasmic reticulum may be conducive to this: these ribosomes have been observed by electron microscopy to be 35 nm apart. Taking in to account the length of the N-terminal region of the TA domain and the ER membrane-spanning region in the newly translated peptide, any newly synthesized peptide must be 55 nm in length to permit N-terminal binding with other ribosome associated transcripts. As human tenascin-C transcripts have been recorded at 86.6 nm in length when folded, 172 it is argued that the N-terminal heptad repeats on newly synthesized tenascin-C transcripts could engage each other and form the hexabrachion in a co-translational manner. 171 In concordance with this, tenascin-R is shorter than tenascin-C and has previously been observed to form only dimers and trimers, but not hexamers; perhaps because the polypeptide chain is too short to allow interactions with 6 other transcripts simultaneously.
In the second model, the hexabrachion has been described as a composite of 2 trimers; each of which are stabilized by coiled-coil interactions prior to dimerization of these 2 subunits into the hexabrachion. 170 This description concurs with preliminary electron micrograph images of the hexabrachion by Erickson and Inglesias, which revealed the presence of a single central globular domain tethered by 2 T-junctions, each in turn bound to 3-arms. In this model, hexabrachion assembly is described as a 2-step process dependent upon key Cysteine residues and a conserved glutamic acid residue. Site-specific mutagenesis was utilized to create numerous N-terminal tenascin-C polypeptide fragments which were then analyzed by far-UV circular dichroism for signs of secondary structure development. In this model the tenascin-C monomers form homotrimer intermediates stabilized at the N-terminal heptad repeats by a parallel 3-stranded a-helical coiled-coil (Fig. 3) . This conformation clusters the 3 TA domains from each homotrimer together (Fig. 3) , allowing 2 homotrimers to bind via their respective TA domains by a high concentration of weak homophillic interactions. 170 The substitution of the amino acid residues present within or nearby the N-terminal heptad repeats can significantly alter the hexabrachion assembly process. Substitution of the N-terminal C-64 residue with glycine results in the formation of trimeric tenascin-C intermediates suggesting a functional role for C-64 in joining trimeric intermediates into hexabrachions, perhaps by disulfide bonding. No other N-terminal Cysteine residue is considered essential for hexabrachion assembly, because site directed mutagenesis of C other than C-64 within the N-terminal heptad repeat region (C-111, 113, 146, 147) still results in the secretion of hexamers from the cell regardless of whether conducted on individual Cysteine or in pairwise combinations. 173 Substitution of all Cysteine residues simultaneously at positions 111, 113, 140, 146 and 147 did not prevent hexabrachion formation, with the majority of oligomers containing over 4 subunits. However subsequent mutation of C-64 resulted in tenascin-C monomers, compounding the importance of C-64 in tenascin-C oligomerization via di-sulfide bonds. 173 Substitution of a conserved glutamic acid-130 with alanine or leucine at heptad position e, abolishes the interaction between the residue at this position and hydrophobic residues at positions a and d. This allows for more efficient packing of hydrophobic residues within the heptad to increase the number of a-helices which can join the coiled-coil from 3 to 4; forming a 4 stranded a-helical coiled-coil. 170 Normally, E130 forms a salt-bridge linkage with arginine-125 in a preceding heptad on an adjacent tenascin-C polypeptide chain.
While hexabrachions are often formed as homotypic molecules comprised of identical subunits, there are instances where heterotypic molecules can be formed. Kammerer et al. 170 demonstrated that 2 triplets of tenascin-C trimers; one missing both the FNIII and FBG domain, were able to heterodimerize forming a heterotypic hexabrachion. Furthermore, smaller oligomers comprising of 2-5 tenascin-C molecules have also been Figure 3 . Hexabrachion assembly is a 2-step process. Multimerization of the N-terminal region of tenascin-C during hexabrachion assembly. 1. The N-terminal region of 3 tenascin-C monomers. Black cylinders represent the N-terminal heptad repeat residues 118-145, and gray circles represent TA domains. 2. The N-terminal heptads contain 3 cysteine-rich heptad repeats with hydrophobic (h) and charged (c) amino acid residues arranged in the conformation hxxhcxc. These monomers form an intermediary trimer which is stabilized by a-helical coiled-coil interactions between the N-terminal domains of the monomers. Three. The oligomerization of the adjacent TA domains increases homophillic binding affinity between the 2 trimers, which bind to form the hexabrachion. Disulfide bonds stabilize the hexabrachion but are not required for its formation (Adapted from Kammerer et al. identified, although it is not known whether these smaller isoforms are deliberately assembled in this manner, or if they are merely remnants of hexabrachions degraded by proteases. 172 Post-translational modification of tenascin-C The assembly of the hexabrachion from tenascin-C monomers reportedly takes only 5 minutes, with a rate limiting step in tenascin-C biosynthesis coming at the point of transport from the endoplasmic reticulum to the golgi apparatus. 171 This is indicative of substantial post-translational modification of tenascin-C and indeed this molecule has been shown to be glycosylated.
Human tenascin-C possesses 26 potential N-glycosylation sites, of which 2 are in the TA domain, 2 are in the EGF-L repeat region, 21 are in the FNIII domain, and 1 is in the FBG domain (Fig. 4) . 23, 174 Analysis of the human tenascin-C cDNA sequence revealed a cluster of 10 potential N-linked glycosylation sites within the alternatively spliced FNIII repeats A1-A4, within 2 clusters given as NLT-X 11 -NWT-X 23 -NLT-X 63 -NWT-X 23 -NLT. Three further putative N-glycosylation sites were identified in human FNIII B, 19, 23 and further analysis with the NetNGlyc 1.0 Server revealed 4 more predicted N-glycosylation sites in the FNIII AD1 and AD2 domains. 174 In chicken tenascin-C, 17 potential N-glycosylation sites were identified by gene analysis, 6 of which were located in the FNIII AD1 and AD2 domains. 38 Analysis of the human tenascin-C peptide sequence with the NetOGlyc 4.0 Server tool; which predicts mucin type GalNAc O-glycosylation sites in mammalian proteins, predicts 34 putative O-glycosylation sites within tenascin-C. 175 Of these, 8 were located in the TA domain, 2 within the EGF-L repeat region and 24 within the FNIII domain, while none were located in the FBG domain (Fig. 4) . 175 At first glance, the distribution of potential O-glycosylation sites within tenascin-C clearly contrasts with that of N-glycosylation sites. O--glycosylation sites are densely arranged within the TA domain and FNIII 1-5, perhaps suggestive of a role in modulating macromolecular assembly and cell adhesion processes. By contrast, N-glycosylation sites are predominantly found within the alternatively spliced FNIII and may therefore be implicated in mechanisms related to development and tumorigenesis.
Confirmation of tenascin-C glycosylation derived from studies where purified human or chicken tenascin-C was treated with glycoside hydrolase enzymes and revealed changes in apparent Mr when subject to reducing-PAGE. Treatment of affinity purified chick embryonic fibroblast tenascin-C with endoglycosidase-F, was shown in 2 studies to result in a »20 kDa, 176 and »10 kDa, 50 reduction in apparent Mr of all 3 tenascin-C splice variants detected. Additionally, treatment with neuraminidase resulted in a 10 kDa reduction in Mr of all gradient purified human glioma and chicken embryonic fibroblast tenascin-C variants detected. 169 All together, these data suggest that carbohydrates contribute significantly to the mass of tenascin-C in humans and chickens, and that the most active glycosylation sites must exist within the constitutively expressed portion of the molecule, as in each study the Mr of all tenascin-C splice variants was affected equally by endoglycosidase-F and neuraminidase treatment. Not much is known about the tissue specific expression patterns and the functional significance of tenascin-C glycosylation beyond studies performed on the HNK-1 epitope. 72 The HNK-1 epitope, is presented on either an N-or O-linked oligosaccharide and believed to play a role in mediating cell adhesion and substrate binding processes. HNK-1 is distributed on a range of neural cell adhesion molecules; [73] [74] [75] and also in some lymphocyte subsets. In tenascin-C this epitope is found in isoforms containing FNIII-A1,A2,A4,B,C,D and which promoted NSC proliferation via modulating the expression of the EGF-R. 71 In this way the presence of glycosylation sites on alternatively spliced FNIII subunits confers greater control of protein function which can be regulated by alternative splicing.
Glycosylation of tenascin-C is likely to significantly impact its ability to modulate cell adhesive and protein binding functions. This may occur via the blocking of receptor and protein binding sites by large branched carbohydrate chains, which obscure tenascin-C from potential binding partners. It is perhaps via this mechanism that the collagen binding affinity of vitronectin is reduced upon glycosylation, 177 and that fibroblast cell adhesion and spreading is improved following a lack of FN glycosylation. 178 In contrast, the addition of new carbohydrate epitopes to tenascin-C may enhance protein and cell interactions, for example sialylation of vitronectin is required for rat hepatic stellate cell spreading, 179 and O-glycosylated oncofetal FN induces epithelial to mesenchymal transition in lung cancer cells in synergy with TGFb. 180 Tenascin-C glycosylation may confer a strategy by which the protein is protected from proteolytic degradation. An early study on rat FN revealed that less glycosylated variants exhibit a greater rate of protease degradation, 181 indicating early on that FN glycosylation protects the protein from fragmentation; therefore a similar protective mechanism may be conserved in tenascin-C. The abundance of putative N-glycosylation sites within the alternatively spliced FNIII A1-D closely associate with the FNIII domains which are susceptible to protease degradation by MMP-1, -2, -3 and -7;
96,97 and may therefore exist to improve the half-life of tenascin-C.
Glycosylation of tenascin-C may offer a mechanism by which macromolecular assembly of the hexabrachion can be regulated by the expression of glycosyltransferase enzymes. The impact of glycosylation on multimer assembly is observed in vitronectin, where a reduced glycosylation state is associated with increased multimer size. 177 It is therefore possible that the prevalence of Nand O-glycosylation sites within in the TA domain of tenascin-C is so high in order to function in a manner designed to interfere with macromolecular assembly of the hexabrachion, which may therefore indirectly affect the ability of the HXB to integrate into the ECM, although this is just speculation.
Despite a wealth of evidence revealing that tenascin-C is glycosylated, specific glycosylation sites have not yet been characterized in the protein, and as a result it is not known how many of the putative N-and O-glycosylation sites are active. Although glycosylation of tenascin-C is understood to modulate cell adhesion, substrate binding and cell proliferation processes, there are likely many more functions yet to be discovered. Further studies are required to advance our understanding of the exciting role played by tenascin-C glycosylation in modifying cell behavior.
Assembly of tenascin-C into a fibrillar matrix
Once suitably modified, the export of glycosylated tenascin-C from the golgi is rapid, with hexabrachions taking as little as 45 minutes to be detected in the conditioned culture medium of U-138 glioma cells after addition of a labeling medium. 171 Tenascin-C is incorporated into the ECM in a manner which is dependent upon the presence of heparan sulfate proteoglycans (HSPGs). Chung and Erickson., generated Chinese hamster ovary cell mutants with a total block in heparin sulfate and chondroitin sulfate synthesis; this blockade resulted in the failure of the cells to assemble a FN matrix, and no tenascin-C was incorporated into the ECM as a result. 182 The generation of a tenascin-C rich ECM has previously been shown to be dependent upon a template of FN and a5, av and b1 integrins. 183 It may be that once incorporated into the ECM, tenascin-C stabilizes FN as tenascin-C knockout mice generally exhibit reduced FN deposition. 15, 184 Tenascin-C may bind to proteoglycan molecules which are themselves bound to FN fibrils; in support of this an analysis revealed a co-localization between perlecan, FN and tenascin-C. Perlecan binds the constitutive FNIII 3-5 of tenascin-C, and this binding is enhanced in the short tenascin-C isoform (»190 kDa). The insertion of alternatively spliced FNIII repeats after FNIII 5 results in an attenuation of perlecan-tenascin-C binding; 182 and could possibly reduce adhesion in cells expressing longer isoforms of tenascin-C, as is observed in cancer. Another factor in matrix formation is the ECM molecule periostin, which has been shown to aid incorporation of tenascin-C into the ECM, albeit through a currently unknown mechanism. 185 It is not clear how tenascin-C may be affected by incorporation into a 3-dimensional matrix, a process very likely to change the conformation of this molecule, perhaps exposing or concealing specific domains and binding sites. Moreover, it is not known how tenascin-C signals as part of a multicomponent ECM, where interaction with other matrix residents may affect the availability of binding sites and where molecules can synergistically regulate cell behavior. What is clear is that the conformation of tenascin-C does have profound effects on its function; this is evidenced by data showing that soluble tenascin-C binds readily to FN in glycerol gradients assays, 129 where the extended conformation of both proteins appear to favor interaction. 186 Conversely, FN does not bind to tenascin-C that has been immobilized onto ELISA plates, but tenascin-C can bind to immobilized FN. 39, 129, 187, 188 As such the context and conformation of tenascin-C should be considered major players in defining ECM function.
Proteolytic processing of tenascin-C One other means of regulating tenascin-C function is proteolytic cleavage. Fragments of tenascin-C have been reported in swabs from individuals with gingivitis, 189 chronic venous leg ulcer exudates, 164 and atherosclerotic plaques 190 among other locations.
Mice lacking MMP-7 191 or MMP-9 192 exhibited lower levels of tenascin-C and tenascin-C fragments after myocardial infarction, suggesting that these metalloproteases can degrade tenascin-C in vivo. In contrast, MMP-19 null mice exhibited elevated tenascin-C protein during a model of asthma, indicating that MMP-19 may prevent the accumulation of tenascin-C. 193 Tenascin-C is also susceptible to proteolytic degradation by MMPs-1, 2, 3 and 7 in vitro with the majority of MMP cleavage sites located within the alternatively spliced region of the protein, making long tenascin-C isoforms more susceptible to fragmentation than shorter isoforms. 97 MMP-7 cleaves all tenascin-C isoforms by removing the 16 kDa N-terminal knob, but it also digests FNIII A3-D within the alternatively spliced region; its ability to digest AD1 and AD2 is not yet known. 97 However, in chronic wounds tenascin-C fragmentation was not inhibited by EDTA and E64 ruling out a role for MMPs and cysteine proteases. It was subsequently confirmed that tenascin-C was digested by leucocyte elastase and possibly other serine proteases. 164 Furthermore, a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) -5 has demonstrated an ability to cleave tenascin-C into fragments of which some correspond to the N-terminal TA domain, 194 with specific tenascin-C fragments identified as inducers of cartilage matrix degradation. 195 Degradation of tenascin-C results in modulation of tissue protein levels, a process key to limiting tenascin-C expression in situations where transient expression is vital, for example in the developing embryo and in healing wounds. The reduction over time of longer variants compared to shorter variants fits well with data showing that longer isoforms are more readily cleaved. Proteolysis also releases smaller fragments from large multimodular proteins that exhibit quite different functions to the intact molecule. For example, fragmented EGF-L domains of tenascin-C induce apoptosis in cultured smooth muscle cells (SMCs) in contrast to full length tenascin-C, 190 and FN matrix assembly is unaffected by full-length tenascin-C, but is inhibited by the FNIII domains or the FBG domain of tenascin-C. 196 Similarly, cleavage of tenascin-C within the FNIII A3 subunit by MMP-2 generates a cryptic binding site within FNIII A2 which permits interaction with heparan sulfated side-chains of syndecan-4 to promote b1 integrin clustering and cell spreading. 97, 132 Finally, full-length tenascin-C is found to be anti-adhesive and to prevent FN-mediated cell spreading of T98G glioblastoma cells, but this effect was lost following cleavage with the metalloprotease meprin b.
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Summary and Conclusions
Following tenascin-C through its life cycle, from the switching on of TNC, through transcription, translation, and protein modification, all the way though to its degradation, reveals a number of mechanisms by which different forms of this molecule are created. Moreover, it is clear that the spatial and temporal control of these events enables the expression of precise tenascin-C forms with distinct functions designed to carry out specific tasks at the right time and place. The molecular events that enable different stimuli to induce the expression of specific spliced variants of tenascin-C remain to be elucidated. However, the way in which the inclusion of alternatively spliced FNIII domains with unique interaction sites confers new binding capabilities or susceptibilities to proteolytic cleavage to tenascin-C is exemplified in many tissues during development and in tumors. Conversely, the inclusion of extra FNIII repeats that interrupt existing binding sites, causing loss of a particular function, is also observed at these locations. Post translational modification of tenascin-C has not yet been extensively studied but already data suggest that glycosylation can have a profound effect on its function. Moreover, it is emerging that the architecture of tenascin-C matters; its assembly into a fibrillar matrix at the cell surface impacts the conformation of this molecule, potentially exposing cryptic binding sites or covering exposed binding sites, and it will be of great interest to determine precisely how tenascin-C acts within the context of complex, 3D tissue environments. Finally, even proteolytic destruction of tenascin-C creates collateral damage that confers novel functions to this molecule. The destruction of existing binding sites and generation of smaller fragments with new binding sites can drive entirely novel processes compared to the intact molecule. It seems that the more we learn about this extraordinary matrix glycoprotein, the more complex and intricate the story becomes.
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